Oncology Portfolio Intelligence Platform

Oncology Portfolio Decision Intelligence

Comprehensive portfolio intelligence for Mays Cancer Center, powered by OriginCV across every stage of the pharma lifecycle.

Tracking 48+ therapeutic programs across 5 tiers — from PROTAC degraders to radioligand therapy, discovery through commercialization.

48+

Therapeutic Programs

20+

Clinical Trials

NCI

Cancer Center Designation

$50M+

Total Funding

Featured Molecules

Six molecules with full deep-dive intelligence across the oncology lifecycle.

DT2216

PROTACTarget: BCL-XLStage 3: Phase 1 Clinical

Phase

1/2

Explore DT2216 →

186RNL (Rhenium Obisbemeda)

NanoliposomeTarget: GBM tumorsStage 4: Phase 2 Clinical

Phase

1/2

Explore 186RNL →

Amuvatinib (MP-470)

Small MoleculeTarget: c-Kit/c-Met/PDGFRStage 4: Phase 2 Clinical

Phase

1/2 (completed)

Explore Amuvatinib →

Sacituzumab Govitecan (GBM)

ADCTarget: Trop-2Stage 3: Phase 1 Clinical

Phase

Explore SG-GBM →

BSI-082

mAbTarget: SIRPαStage 2: Preclinical Development

Phase

Explore BSI-082 →

Pluvicto (177Lu-PSMA-617)

RLTTarget: PSMAStage 8: Peak Commercialization

Status

Commercial

Explore Pluvicto →

View Full Portfolio (48+ molecules) →

Portfolio Lifecycle Map

Where each molecule sits in the 12-stage pharma lifecycle.

OriginCV Intelligence Capabilities

AI-powered decision support across the oncology portfolio.

Clinical Trial Intelligence

Clinical

Real-time monitoring of competing trials, enrollment benchmarking, and endpoint analysis across ClinicalTrials.gov and published literature.

Value Delivered

Identifies competitive threats 6-12 months ahead of readout.

Biomarker-Driven Enrollment Optimization

Clinical

Analyzes biomarker prevalence, screening failure rates, and geographic distribution to optimize site selection and enrollment strategy.

Value Delivered

Reduces screening failures by 25-40% through biomarker-informed site placement.

Regulatory Pathway Analysis

Regulatory

Precedent analysis of FDA decisions for similar modalities, accelerated approval requirements, and breakthrough therapy designation strategies.

Value Delivered

Optimizes regulatory strategy with precedent-based predictions.

KOL Sentiment Simulation

Commercial

Models key opinion leader reactions to clinical data, competitive events, and regulatory decisions using persona-scenario matrices.

Value Delivered

Anticipates adoption barriers and messaging requirements.

Coverage & Reimbursement Intelligence

Market Access

Monitors Medicare NCD/LCD policies, J-code assignments, prior authorization requirements, and payer coverage decisions.

Value Delivered

Proactive market access strategy with policy change alerts.

Competitive Landscape Tracking

Strategy

Continuous monitoring of competitor pipeline advances, conference presentations, and patent filings across therapeutic areas.

Value Delivered

Comprehensive competitive positioning for investment decisions.

Evidence Synthesis Engine

Clinical

Aggregates clinical evidence from trials, real-world data, and publications into structured assessments with quality scoring.

Value Delivered

Accelerates evidence-based decision-making across the portfolio.

Grant & Funding Intelligence

Strategy

Tracks CPRIT, NCI, DoD, and foundation funding opportunities aligned to active research programs.

Value Delivered

Identifies $10M+ in additional funding opportunities annually.

Portfolio Lifecycle Analytics

Strategy

Tracks lifecycle position across the portfolio to identify development gaps, resource allocation needs, and strategic priorities.

Value Delivered

Optimizes resource deployment across 4 active molecules.

Institutional Overview

NCI-Designated Cancer Center serving South Texas.

Institute for Drug Development (IDD)

Director: Dr. Daruka Mahadevan

Phase 1-focused clinical research unit specializing in first-in-human oncology trials. One of the most experienced early-phase trial units in the U.S.

40+

Active Programs

500+

Annual Patients

Center for Innovative Drug Discovery (CIDD)

Co-Directors: Dr. Daohong Zhou, Dr. Stanton McHardy

Translational research center bridging discovery chemistry and clinical development. Pioneered PROTAC-based degrader therapeutics targeting BCL-XL for hematologic malignancies.

Key Platforms

PROTAC degrader platform (DT series)CRISPR-based functional genomics screeningHigh-throughput drug sensitivity testing

Decision Cadences

Governance forums driving portfolio decisions.

Portfolio Quarterly Business Review

Quarterly

Comprehensive review of all 4 molecules covering clinical progress, competitive landscape, regulatory milestones, and resource allocation.

5 participants

Clinical Operations Review

Monthly

Trial enrollment tracking, safety monitoring, and protocol compliance across all active studies.

4 participants

Data Safety Monitoring Committee

Per protocol

Independent review of accumulating safety and efficacy data with authority to recommend trial modifications.

4 participants

Translational Science Meeting

Bi-weekly

Review of correlative science, biomarker data, and discovery-to-clinic pipeline progress across CIDD programs.

4 participants

KOL Advisory Board

Semi-annual

External expert input on trial design, competitive positioning, and market access strategy.

4 participants

Regulatory Strategy Council

Per program milestone

FDA interaction planning, designation strategy, and submission timeline coordination.

4 participants